Cargando…
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
Background/Aim: Radium-223 dichloride ((223)RaCl(2)) represents a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients dealing with symptomatic bone metastases. The identification of baseline variables potentially affecting the life-prolonging role of (223)RaCl(2)...
Autores principales: | De Feo, Maria Silvia, Frantellizzi, Viviana, Bauckneht, Matteo, Farcomeni, Alessio, Filippi, Luca, Rizzini, Elisa Lodi, Lavelli, Valentina, Stazza, Maria Lina, Di Raimondo, Tania, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Filippo, Mammini, Mammucci, Paolo, Marongiu, Andrea, Monari, Fabio, Rubini, Giuseppe, Spanu, Angela, De Vincentis, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136348/ https://www.ncbi.nlm.nih.gov/pubmed/37189721 http://dx.doi.org/10.3390/biomedicines11041103 |
Ejemplares similares
-
Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study
por: Frantellizzi, Viviana, et al.
Publicado: (2020) -
Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-resistant Prostate Cancer Patients Candidates to 223RaCl Treatment
por: Frantellizzi, Viviana, et al.
Publicado: (2019) -
Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021) -
Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020) -
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
por: Bauckneht, Matteo, et al.
Publicado: (2021)